Diabetes & Obesity in HFpEF: New targets in heart failure management
Prof. De Boer summarises the interplay between obesity, diabetes and HFpEF, and how the first two conditions may be managed, to minimize their impact on the course of HFpEF.
Video navigation menu
- The rising trend in obesity prevalence affects management of HFpEF 0:21
- How are obesity and HFpEF related? 2:45
- Obesity is not a uniform condition: the type of adiposity affects the HFpEF phenotype 4:21
- Diabetes is an independent predictor for HFpEF and the conditions often co-occur and 7:45
- Diabetes has a broad range of effects that negatively affect the HFpEF phenotype 8:56
- Treatment options of T2DM in HF patients 10:07
This lecture by Prof. De Boer was part of a CME accredited symposium: Novel concepts and treatments of comorbidities in Heart Failure with Preserved Ejection Fraction held at ESC Heart Failure 2018 in Vienna.
Prof. Rudolf de Boer is a Clinical Cardiologist and a Professor of (translational) Cardiology at the University Medical Center Groningen, the Netherlands. His clinical interests are cardiogenetics, echocardiography and end stage heart failure including VAD therapy and transplant. His research group focuses on novel genes involved in cardiac remodeling, fibrosis, and metabolic changes and diabetes.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Novartis and NovoNordisk.